Literature DB >> 18063690

Cell-specific activation of the human skeletal alpha-actin by androgens.

Mei Hua Hong1, Hong Sun, Cheng He Jin, Mark Chapman, Junlian Hu, William Chang, Kelven Burnett, Jon Rosen, Andres Negro-Vilar, Jeffrey N Miner.   

Abstract

Although it is evident that androgens increase muscle mass and strength, little is known about the critical molecular targets of androgens in skeletal muscle. In rodents, the skeletal alpha-actin gene is a tissue-specific gene expressed only in the levator ani and other skeletal muscles but not in the prostate or preputial gland, the well-known androgen target tissue. We identified tissue-specific androgen-regulated genes in the skeletal muscle in rats after oral administration of androgens and focused on androgen-dependent up-regulation of the skeletal alpha-actin gene. To investigate the mechanism of action, an in vitro system with various cell lines and a series of deletion mutants of the alpha-actin promoter were used. The human skeletal alpha-actin promoter was activated by androgens in the muscle cell line C2C12 but not in the liver, prostate, or breast cancer cell lines in which exogenous human androgen receptor is expressed. The sequence of the promoter is sufficient for cell-specific androgen response, providing a model for the tissue specificity demonstrated in vivo. Using a series of deletion mutants, the androgen response can be maintained using just the proximal promoter region. The importance of androgen regulation of this small portion of the human skeletal alpha-actin promoter was demonstrated by the correlation between muscle and the alpha-actin promoter activity for an array of selective androgen receptor modulators (SARMs), including an orally active SARM LGD2226. Taken together, the results suggest that the regulation of skeletal alpha-actin by androgens/SARMs may represent an important model system for understanding androgen anabolic action in the muscle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18063690     DOI: 10.1210/en.2007-0530

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  GH overexpression causes muscle hypertrophy independent from local IGF-I in a zebrafish transgenic model.

Authors:  Rafael Y Kuradomi; Márcio A Figueiredo; Carlos F C Lanes; Carlos E da Rosa; Daniela V Almeida; Rodrigo Maggioni; Maeli D P Silva; Luis F Marins
Journal:  Transgenic Res       Date:  2010-07-17       Impact factor: 2.788

2.  Sexual differentiation of the spinal nucleus of the bulbocavernosus is not mediated solely by androgen receptors in muscle fibers.

Authors:  Lee Niel; Amit H Shah; Gareth A Lewis; Kaiguo Mo; Diptendu Chatterjee; Shannon M Fernando; Mei Hua Hong; William Y Chang; Peter Vollmayr; Jon Rosen; Jeffrey N Miner; D Ashley Monks
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

3.  Androgen receptor polyglutamine repeat length affects receptor activity and C2C12 cell development.

Authors:  Ryan L Sheppard; Espen E Spangenburg; Eva R Chin; Stephen M Roth
Journal:  Physiol Genomics       Date:  2011-08-09       Impact factor: 3.107

4.  Enhanced evaluation of selective androgen receptor modulators in vivo.

Authors:  M Otto-Duessel; M He; T W Adamson; J O Jones
Journal:  Andrology       Date:  2012-08-28       Impact factor: 3.842

5.  Regulation of STARS and its downstream targets suggest a novel pathway involved in human skeletal muscle hypertrophy and atrophy.

Authors:  Séverine Lamon; Marita A Wallace; Bertrand Léger; Aaron P Russell
Journal:  J Physiol       Date:  2009-03-02       Impact factor: 5.182

6.  Neural Mechanisms Underlying the Disruption of Male Courtship Behavior by Adult Exposure to Di(2-ethylhexyl) Phthalate in Mice.

Authors:  Carlos Dombret; Daphné Capela; Kevin Poissenot; Caroline Parmentier; Emma Bergsten; Cédric Pionneau; Solenne Chardonnet; Hélène Hardin-Pouzet; Valérie Grange-Messent; Matthieu Keller; Isabelle Franceschini; Sakina Mhaouty-Kodja
Journal:  Environ Health Perspect       Date:  2017-09-01       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.